問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Infectious Disease

Division of Thoracic Medicine

更新時間：2023-09-19

莊祐中
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊祐中

List

8Cases

2021-02-01 - 2026-12-31

Phase III

Active
A phase III, randomized, evaluator-blind, two-stage, two-way cross-over, active- and placebo-controlled, simulation study to evaluate the effectiveness and safety of Easy Antiseptic Cloth with 2% chlorhexidine gluconate (Aqua) as the topical antiseptics in healthy volunteers

  • Condition/Disease

    Disinfect before surgery

  • Test Drug

    Easy Antiseptic Cloth with 2% CHG(Aqua)

Participate Sites
5Sites

Recruiting5Sites

2023-12-08 - 2024-09-30

Phase II/III

Completed
AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS

  • Condition/Disease

    Respiratory Syncytial Virus Infection

  • Test Drug

    SisunatovirPlacebo

Participate Sites
8Sites

Recruiting7Sites

Terminated1Sites

2018-08-01 - 2023-01-31

Phase III

Completed
A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO-Β-LACTAMASE (MBL)

  • Condition/Disease

    SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO -Β-LACTAMASE (MBL)

  • Test Drug

    PF-06947387 (Aztreonam –Avibactam)

Participate Sites
3Sites

Not yet recruiting3Sites

2018-05-01 - 2023-05-17

Phase III

Completed
A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS

  • Condition/Disease

    SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS

  • Test Drug

    PF-06947387 (Aztreonam –Avibactam)

Participate Sites
7Sites

Not yet recruiting6Sites

Terminated1Sites

2014-01-01 - 2018-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-04-01 - 2019-12-31

Phase III

Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo) for Patients Receiving Co-Formulated TDF, Emtricitabine and Efavirenz (Atripla) With Viral Suppression in Taiwan

  • Condition/Disease

    HIV Infections

  • Test Drug

    Efavirenz / Tenofovir Disoproxil Fumarate / Lamivudine 400/300/300 mg Tablet

Participate Sites
2Sites

Terminated2Sites

2015-09-01 - 2017-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneumonia (CABP)

  • Condition/Disease

    The initial targeted indications are serious skin infections (ABSSSI), community acquired lower respiratory tract infections (CABP) and urinary tract infections

  • Test Drug

    Omadacycline (PTK 0796)

Participate Sites
5Sites

Terminated5Sites

2019-11-17 - 2021-12-31

Phase III

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

  • Condition/Disease

    Lower Respiratory Tract Parainfluenza Infection

  • Test Drug

    DAS181

Participate Sites
2Sites

Recruiting2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB